WO2003097082A3 - Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies - Google Patents

Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies Download PDF

Info

Publication number
WO2003097082A3
WO2003097082A3 PCT/US2003/015874 US0315874W WO03097082A3 WO 2003097082 A3 WO2003097082 A3 WO 2003097082A3 US 0315874 W US0315874 W US 0315874W WO 03097082 A3 WO03097082 A3 WO 03097082A3
Authority
WO
WIPO (PCT)
Prior art keywords
crohn
psoriasis
disease
treatment
gamma antibodies
Prior art date
Application number
PCT/US2003/015874
Other languages
French (fr)
Other versions
WO2003097082A2 (en
Inventor
Rolf Ehrhardt
Dan Levitt
Beth Layug
Don O'neill
Nancy Wedel
Lars Ostberg
Original Assignee
Protein Design Labs
Rolf Ehrhardt
Dan Levitt
Beth Layug
Don O'neill
Nancy Wedel
Lars Ostberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs, Rolf Ehrhardt, Dan Levitt, Beth Layug, Don O'neill, Nancy Wedel, Lars Ostberg filed Critical Protein Design Labs
Priority to JP2004505078A priority Critical patent/JP2005529152A/en
Priority to CA002486147A priority patent/CA2486147A1/en
Priority to EP03753102A priority patent/EP1506002A4/en
Priority to AU2003231802A priority patent/AU2003231802A1/en
Publication of WO2003097082A2 publication Critical patent/WO2003097082A2/en
Publication of WO2003097082A3 publication Critical patent/WO2003097082A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a method of treating autoimmune diseases. In particular,it provides a method for the treatment of Crohn's disease or psoriasis comprising administering to a subject in need thereof a therapeutically effective amount of an antibody against interferon gamma.
PCT/US2003/015874 2002-05-17 2003-05-16 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies WO2003097082A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2004505078A JP2005529152A (en) 2002-05-17 2003-05-16 Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
CA002486147A CA2486147A1 (en) 2002-05-17 2003-05-16 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
EP03753102A EP1506002A4 (en) 2002-05-17 2003-05-16 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
AU2003231802A AU2003231802A1 (en) 2002-05-17 2003-05-16 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15074202A 2002-05-17 2002-05-17
US10/150,742 2002-05-17
US38331002P 2002-05-22 2002-05-22
US60/383,310 2002-05-22

Publications (2)

Publication Number Publication Date
WO2003097082A2 WO2003097082A2 (en) 2003-11-27
WO2003097082A3 true WO2003097082A3 (en) 2004-12-09

Family

ID=29552737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/015874 WO2003097082A2 (en) 2002-05-17 2003-05-16 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies

Country Status (5)

Country Link
EP (1) EP1506002A4 (en)
JP (1) JP2005529152A (en)
AU (1) AU2003231802A1 (en)
CA (1) CA2486147A1 (en)
WO (1) WO2003097082A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0695189T3 (en) 1992-12-29 1999-08-09 Genentech Inc Treatment of inflammatory bowel disease with IFN-gamma inhibitors
CN101151277B (en) * 2005-01-27 2013-11-13 诺维莫尼公司 Anti-interferon gamma antibodies and methods of use thereof
JP2009534428A (en) * 2006-04-25 2009-09-24 インターツェル・アクチェンゲゼルシャフト HCV vaccination
RU2497545C2 (en) * 2008-03-18 2013-11-10 Эбботт Лэборетриз Method of treating psoriasis (versions)
KR20140097336A (en) 2011-11-23 2014-08-06 암젠 인크 Methods of treatment using an antibody against interferon gamma
MA41271A (en) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc METHODS OF USE OF OLIGONUCLEOTIDES ANTISENS TARGETING SMAD7
EA037532B1 (en) 2015-05-07 2021-04-08 Новиммун Са Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
US6558661B1 (en) * 1992-12-29 2003-05-06 Genentech, Inc. Treatment of inflammatory bowel disease with IFN-γ inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE69942671D1 (en) 1998-12-01 2010-09-23 Facet Biotech Corp HUMANIZED ANTIKOERPER AGAINST GAMMA INTERFERON
US20050019323A1 (en) * 2002-05-22 2005-01-27 Protein Design Labs, Inc. Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558661B1 (en) * 1992-12-29 2003-05-06 Genentech, Inc. Treatment of inflammatory bowel disease with IFN-γ inhibitors
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1506002A4 *

Also Published As

Publication number Publication date
JP2005529152A (en) 2005-09-29
AU2003231802A1 (en) 2003-12-02
CA2486147A1 (en) 2003-11-27
WO2003097082A2 (en) 2003-11-27
EP1506002A4 (en) 2006-06-07
EP1506002A2 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
HUS1600042I1 (en) Therapeutic use of anti-CS1 antibodies
WO2005102387A3 (en) Therapeutic use of anti-cs1 antibodies
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
WO2004032868A3 (en) Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
WO2004068931A3 (en) Amphiregulin antibodies and their use to treat cancer and psoriasis
WO2005080428A3 (en) Anti-epcam immunoglobulins
SI1684770T1 (en) Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
WO2001037874A3 (en) Treatment of psoriasis by using an antibody to tnf alpha
WO2002062383A3 (en) Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases
WO2005058358A3 (en) Use of agents derived from ceacam1 for the treatment of inflammatory diseases
WO2001072334A3 (en) Methods for treating disease with antibodies to cxcr3
WO2000044408A3 (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists
WO2005000406A3 (en) Treatment of amyloid- and epileptogenesis-associated diseases
WO2005014653A3 (en) Humanized chicken antibodies
WO2002066037A3 (en) Antiviral method of use
WO2001074993A3 (en) A novel polypeptide - human zinc finger protein 17 and the polynucleotide encoding said polypeptide
WO2001041703A3 (en) Method for treating allergic diseases
WO2004003011A3 (en) Nuclear hormone receptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2486147

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004505078

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003753102

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003753102

Country of ref document: EP